Skip to main content

Table 2 Comparison of various parameters in patients with mild (<33% of hepatocytes affected) or severe (>33% of hepatocytes affected) steatosis and those without steatosis (univariate analysis)

From: Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals

 

No steatosis

(n=82)

Steatosis

(n=102)

Mild steatosis

(n=76)

Severe steatosis

(n=26)

p a

p b

p c

Median age (IQR), yrs

40 (36-45)

41 (37-45)

41 (36-45)

41 (37-48)

0.38

0.66

0.81

Male gender, n (%)

66 (80)

88 (86)

67 (88)

21 (81)

0.32

0.39

0.34

IVDU, n (%)

50 (62)

77 (76)

54 (71)

23 (88)

0.05

0.03

0.11

Alcohol use, n (%)

29 (35)

38 (37)

29 (38)

9 (35)

0.88

0.92

0.82

Median duration of HIV (IQR), yrs

10 (5-14)

12 (8-14)

12 (8-15)

11 (7-13)

0.17

0.23

0.30

Median CD4 cell count (IQR), /mm3

346 (228-560)

308 (227-423)

305 (227-435)

313 (191-398)

0.10

0.24

0.67

HIV RNA<400 copies/ml, n (%)

58 (72)

61 (63)

46 (62)

15 (65)

0.26

0.45

1.0

HCV genotype 3, n (%)

13 (16)

34 (35)

18 (25)

16 (64)

0.005

<.0001

<.0001

Median HCV RNA (IQR), logIU/ml

5.97 (5.65-6.50)

6.30 (6.00-6.72)

6.22 (5.80-6.64)

6.69 (6.27-7.06)

0.003

0.0003

0.004

Median ALT (IQR), U/l

67 (40-119)

87 (54-130)

83 (51-121)

113 (84-132)

0.04

0.01

0.03

Median AST (IQR), U/l

56 (37-78)

77.5 (50-104)

70 (48-102)

78 (59-105)

0.001

0.003

0.33

Median alkaline phosphase (IQR), U/l

90 (70-115)

89 (69-112)

90 (72-113)

80 (65-95)

0.46

0.27

0.15

Median GGT (IQR), U/l

71 (41-139)

87 (43-196)

92 (44-198)

73 (30-180)

0.09

0.09

0.19

Median glycemia (IQR), mmol/l

4.80 (4.30-5.45)

4.92 (4.30-5.22)

4.80 (4.30-5.20)

4.90 (4.35-5.26)

0.79

0.96

0.97

Glycemia 5.6mmol/l, n (%)

16 (21)

17 (17)

12 (16)

5 (21)

0.56

0.77

0.76

Glycemia 7.0mmol/l, n (%)

1 (1)

6 (6)

6 (8)

0 (0)

0.14

0.08

0.33

Median total cholesterol (IQR), mmol/l

4.40 (3.73-5.33)

4.00 (3.30-4.79)

4.01 (3.30-5.03)

3.72 (3.06-4.37)

0.01

0.02

0.30

Median triglycerides (IQR), mmol/l

1.47 (0.97-2.08)

1.51 (0.99-2.20)

1.53 (1.04-2.24)

1.23 (0.90-1.74)

0.86

0.51

0.28

Triglycerides 1.7mmol/l, n (%)

30 (40)

30 (33)

23 (33)

7 (29)

0.33

0.56

0.80

Fibrosis F3-F4, n (%)

12 (15)

31 (30)

25 (33)

6 (23)

0.01

<0.001

1.0

Metavir score activity A2/A3, n (%)

21 (26)

34 (33 )

29 (38 )

5 (19 )

0.28

0.11

0.09

  1. pa Comparison of patients with versus without steatosis (Kruskal-Wallis test for quantitative variables, 2 test or Fisher's exact test for qualitative variables).
  2. pb Comparison of patients with mild or severe steatosis versus without steatosis (Kruskal-Wallis test for quantitative variables, 2 test for qualitative variables).
  3. pc Comparison of patients with mild versus severe steatosis (Kruskal-Wallis/Wilcoxon test for quantitative variables, 2 test or Fisher's exact test for qualitative variables).
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us